trial · primary record
Dexamethasone
Triple Negative Breast Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 17 |
| Primary completion | 2033-05-31 |
| Primary endpoint | Incidence of hypersensitivity reactions (HSRs) requiring reintroduction of dexamethasone |
| Registry ID | NCT07914309 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:41.096Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07914309
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Dexamethasone · approval
- Dexamethasone · compound